August round-up of pharmaceutical and biotech M&A activity

4 September 2018

There were signs that the pharma M&A market was getting back to business as summer drew to a close in the northern hemisphere.

A couple of big players in the industry were among those making acquisitions, and one of them - the diabetes specialist Novo Nordisk (NOV: N) - was responsible for the biggest deal of the month with its $800 million buy of Ziylo.

The biggest total spend on acquisitions during the month was forked out by Emergent BioSolutions (NYSE: EBS), a fast-growing US biotech, which announced two separate deals.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK